ADGN-121 / Aanastra - LARVOL DELTA

KRAS Mutant Gene Editing Abolishes Tumor Growth In Vivo and Overcomes Acquired Resistance to KRASG12C and KRASG12D Small Molecule Inhibitors (ASGCT 2024) - "Recently, KRASG12C inhibitors (sotorasib,adagrasib) have been approved...KRASG12D inhibitors (MTRX-1133 and INCB161734 ) have recently entered clinical development...We demonstrated a synergistic combination between ADGN-121/Abraxane in pancreatic carcinoma and between ADGN-122/Capecitabine in colon Adenocarcinoma...ADGN-121 containing gRNAG12D/mRNACas9 can overcome MRTX1133 resistance in vitro...ADGN-121, and ADGN-122 were effective in invivo targeting selectively the two major KRAS mutations in G12D and G12V, which are present in 4.2% and 3.6% of all cancer patients respectively. Importantly, ADGN-123 and ADGN-121 constitute a potent alternative strategy to overcome resistance associated to small molecule inhibitors of KRASG12C and KRASG12D"

Preclinical • Colon Cancer • Colorectal Adenocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Hepatology • Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • KRAS

Selective deletion of the KRAS mutant gene with ADGN-123 and ADGN-121 peptide-RNA nanoparticles: A new strategy to overcome acquired resistance to KRASG12C and KRASG12D small molecule inhibitors (AACR 2024) - "Recently, KRASG12C inhibitors (sotorasib and adagrasib) have been approved and KRASG12D inhibitor MTRX-1133 has shown preclinical efficacy in KRASG12D mutated cancers...ADGN-121 was evaluated on ASPC-1 and PANC-1 generated clones resistance to MRTX-1133...ADGN treatments were well tolerated, with no signs of clinical toxicity detected after single or repeat administration.Our study provides a proof-of-concept that ADGN complexes can be applied to target driver mutations of cancers in vivo and permanently disrupt the oncogenic alleles, leading to major tumor regression. ADGN-123 and ADGN-121 constitute a potent alternative strategy to overcome resistance associated to small molecule inhibitors of KRASG12C and KRASG12D"

Preclinical • Colorectal Cancer • Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • KRAS

Aanastra Inc to Present Multiple Posters on RNA Therapeutics at the American Association for Cancer Research (AACR) Annual Meeting 2024 (GlobeNewswire) - "Aanastra, Inc...announced poster presentations at the 2024 American Association for Cancer Research (AACR), taking place April 5-10, 2024, in San Diego, CA."

Preclinical • Oncology • Solid Tumor